Evidence map›Paper›PMID 40959509›Full record

ArticleIEEE International Conference on Bioinformatics and Biomedicine workshops. IEEE International Conference on Bioinformatics and Biomedicine2023

Prediction of Drug Targets based on In Vitro Activity Profiles Toward Drug Repurposing for Rare Diseases.

Binghan Xue, Ruili Huang, Qian Zhu, Yanji Xu

Abstract read
In one paragraph

Article in IEEE International Conference on Bioinformatics and Biomedicine workshops. IEEE International Conference on Bioinformatics and Biomedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Binghan XueDivision of Rare Diseases, Research Innovation, National Institutes of Health, Bethesda, U.S.
Ruili HuangDivision of Preclinical Innovation, National Institutes of Health, Bethesda, U.S.
Qian ZhuDivision of Preclinical Innovation, National Institutes of Health, Bethesda, U.S.
Yanji XuDivision of Rare Diseases, Research Innovation, National Institutes of Health, Bethesda, U.S.

Funding

Intramural NIH HHS Z99 TR999999
6 · The paper itself

Abstract

Over 300 million people are suffering from rare diseases, most of which have limited treatment options. Therefore, discovering new treatments for rare diseases is imperative. Drug repurposing, which identifies new uses for approved drugs, is considered one of the viable and risk-managed strategies for disease treatments. To promote the drug repurposing process, we introduced a prediction model to uncover novel relationships between gene targets and chemical compounds. In our previous study, we identified enriched genes for compounds from the Toxicology in the 21st Century program (Tox21) 10K library, to extend that study for enriched gene target prediction, we developed machine learning (ML) models including Support Vector Machine; K-Nearest Neighbors; Random Forest; and extreme gradient boosting (XGBoost), by using Tox21 bioassay screening data. All four models perform well with f1_score over 0.7, and XGBoost has the best performance with four different multi-label prediction embedding algorithms, including Binary Relevance; Label Powerset; Classifier Chain; Multi-Output Classifier. Our study explored a reliable method to predict potential gene targets from in vitro activity profile data toward drug repurposing.

Indexed as

Drug repurposingGene targetsMachine LearningTox21

Identifiers

PMID40959509
PMCPMC12435567

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.